Literature DB >> 21382648

[Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes].

Edelmiro Menéndez Torre1, Francisco Javier Lafita Tejedor, Sara Artola Menéndez, Jesús Millán Núñez-Cortés, Angeles Alonso García, Manuel Puig Domingo, José Ramón García Solans, Fernando Alvarez Guisasola, Javier García Alegría, Javier Mediavilla Bravo, Carlos Miranda Fernández-Santos, Ramón Romero González.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21382648      PMCID： PMC7024946          DOI： 10.1016/j.aprim.2010.07.012

Source DB:  PubMed          Journal:  Aten Primaria        ISSN： 0212-6567            Impact factor:   1.137


× No keyword cloud information.
  76 in total

1.  Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials.

Authors:  Rukmini Rajagopalan; Shrividya Iyer; Mehmood Khan
Journal:  Curr Med Res Opin       Date:  2005-01       Impact factor: 2.580

2.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Authors:  David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

3.  A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin.

Authors:  Azim S Gangji; Tali Cukierman; Hertzel C Gerstein; Charles H Goldsmith; Catherine M Clase
Journal:  Diabetes Care       Date:  2007-02       Impact factor: 19.112

4.  Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

Authors:  Jeffrey A Johnson; Sumit R Majumdar; Scot H Simpson; Ellen L Toth
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

5.  Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

Authors:  G Bolli; F Dotta; L Colin; B Minic; M Goodman
Journal:  Diabetes Obes Metab       Date:  2009-04-13       Impact factor: 6.577

Review 6.  Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.

Authors:  P Raskin
Journal:  Diabetes Obes Metab       Date:  2008-05-20       Impact factor: 6.577

7.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

Review 8.  Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.

Authors:  Bo Ahrén
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-08       Impact factor: 4.690

9.  Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin.

Authors:  B Göke; K Hershon; D Kerr; A Calle Pascual; A Schweizer; J Foley; Q Shao; S Dejager
Journal:  Horm Metab Res       Date:  2008-08-22       Impact factor: 2.936

Review 10.  Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?

Authors:  Luc F Van Gaal; Stephen W Gutkin; Michael A Nauck
Journal:  Eur J Endocrinol       Date:  2008-03-05       Impact factor: 6.664
View more
  4 in total

1.  Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain.

Authors:  Pedro Mezquita-Raya; Antonio Ramírez de Arellano; Nana Kragh; Gabriela Vega-Hernandez; Johannes Pöhlmann; William J Valentine; Barnaby Hunt
Journal:  Diabetes Ther       Date:  2017-02-21       Impact factor: 2.945

2.  [Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in Spain].

Authors:  Eduardo José Abad Paniagua; Pedro Casado Escribano; José María Fernández Rodriguez; Francisco J Morales Escobar; Lourdes Betegón Nicolás; Joaquín Sánchez-Covisa; Max Brosa
Journal:  Aten Primaria       Date:  2014-12-30       Impact factor: 1.137

3.  Meeting individualized glycemic targets in primary care patients with type 2 diabetes in Spain.

Authors:  I Miñambres; J J Mediavilla; J Sarroca; A Pérez
Journal:  BMC Endocr Disord       Date:  2016-02-17       Impact factor: 2.763

4.  [Prospective observational study of insulin detemir in patients with poorly controlled type 2 diabetes mellitus initiating insulin therapy for the first time (SOLVE Study)].

Authors:  Domingo Orozco-Beltrán; Sara Artola-Menéndez
Journal:  Aten Primaria       Date:  2015-06-06       Impact factor: 1.137
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.